FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115873524> ?p ?o ?g. }

• W2115873524 endingPage "370" @default.
• W2115873524 startingPage "367" @default.
• W2115873524 abstract "original articleSerum leptin and its relationship with metabolic variables in Arabs with type 2 diabetes mellitus Kamal A. Al-Shoumer, Adnan A. Al-Asousi, Suhail A. Doi, and Bagavathy A. Vasanthy Kamal A. Al-Shoumer Division of Endocrinology and Metabolic Medicine, Mubarak Al-Kabeer Hospital, Kuwait University, Jabriya, Kuwait Department of Medicine, Faculty of Medicine, Kuwait University, Jabriya, Kuwait Search for more papers by this author , Adnan A. Al-Asousi Department of Medicine, Faculty of Medicine, Kuwait University, Jabriya, Kuwait Search for more papers by this author , Suhail A. Doi Division of Endocrinology and Metabolic Medicine, Mubarak Al-Kabeer Hospital, Kuwait University, Jabriya, Kuwait Search for more papers by this author , and Bagavathy A. Vasanthy Department of Medicine, Faculty of Medicine, Kuwait University, Jabriya, Kuwait Search for more papers by this author Published Online:2 Oct 2008https://doi.org/10.5144/0256-4947.2008.367SectionsPDF ToolsAdd to favoritesDownload citationTrack citations ShareShare onFacebookTwitterLinked InRedditEmail AboutAbstractBACKGROUND AND OBJECTIVES: Most studies on serum leptin in type 2 diabetes mellitus have focused on white populations. We studied serum leptin concentrations and parameters related to glycemic control and the association between leptin levels and anthropometric and metabolic factors in Arab patients with type 2 diabetes and in Arab control subjects.SUBJECTS AND METHODS: Ninety-two patients (65 females and 27 males) with type 2 diabetes and 69 matched normal control subjects (48 females and 21 males) were included. Anthropometric measures (including body mass index [BMI] and waist:hip ratio) were assessed in all subjects. After an overnight fast, blood was collected for serum leptin assay. Other metabolic parameters including glucose, insulin, C-peptide, intact proinsulin, insulin resistance index (HOMA-IR), insulin-like growth factor 1 (IGF-1), lipids and hemoglobin A1c (HbA1c) were determined.RESULTS: Fasting serum leptin levels, IGF-1 and high-density lipoprotein (HDL) cholesterol were similar in patients with type 2 diabetes and control subjects. When obese subjects (BMI ≤30 kg/m2) were analyzed separately, serum levels of leptin were significantly lower in patients compared to controls. In contrast, patients had higher fasting glucose, insulin, C-peptide, intact proinsulin, insulin resistance, total cholesterol, triglycerides, HbA1c, and a larger waist circumference and waist-to-hip ratio than controls. Serum leptin correlated positively with BMI, negatively with waist-to-hip ratio, and demonstrated no relationship to other parameters.CONCLUSION: Patients with type 2 diabetes in an Arab ethnic population showed evidence of an unfavorable metabolic profile despite having leptin levels similar to controls. Obesity influences serum leptin levels more significantly in type 2 diabetes, in which leptin levels tends to be low.IntroductionType 2 diabetes mellitus is characterized by defects in insulin action and insulin secretion, free fatty acid metabolism, and fat distribution.1–3 More recently, the adipocyte-derived hormone leptin has been implicated in the regulation of adipose mass4 and has been reported to alter both insulin sensitivity5–7 and insulin secretion.8 Although it is clear that circulating leptin is positively correlated with various measures of adiposity,9 the relationship of diabetes to plasma leptin concentration, independent of adiposity, is less clear.Earlier reports variably suggest that circulating leptin is unchanged,10–14 reduced,15,16 and raised17 in type 2 diabetes. However, studies of humans with untreated type 1 diabetes and animals with insulin deficiency consistently demonstrate that plasma leptin concentration and leptin mRNA are reduced.18–21 The variable results in type 2 diabetes are not surprising given that subjects differed with respect to extent of obesity, age, gender and ethnic group. In the literature, most of the studies on serum leptin in type 2 diabetes have focused on white populations. In this study we investigated leptin concentrations and parameters related to glycemic control in Arabs with type 2 diabetes and in matched normal control subjects. We also assessed the relationship between leptin and anthropometric and metabolic variables.SUBJECTS AND METHODSNinety-two Arab patients with type 2 diabetes mellitus and 69 normal control subjects were included in the study. The patients and controls were matched by ethnic group, age, gender and body mass index (BMI). Patients had been diabetic for a median of 6 years (range, 0.5–20.5 years). They were recruited from the endocrine clinics of Mubarak Al-Kabeer Hospital and the Hawalli region in Kuwait. Twelve patients were treated with diet only, 54 patients were treated with oral anti-diabetic agents and 26 were on insulin therapy. No patient or control had other known illness and none of the patients or controls was taking medications other than their anti-diabetic therapy (except for 42 patients taking either ACE inhibitors or angiotensin receptor blockers, 36 taking either statins or fibrates and 39 taking low-dose aspirin). Controls were healthy subjects who in the last 12 months were not taking any medication and had no family history of diabetes mellitus. The study protocol was approved by the local ethics committee and patients gave written informed consent.Anthropometric measurements (including waist and hip) and blood pressures were assessed in all subjects. The waist and hip circumferences were measured using a flexible measuring tape directly applied to the subject’s skin. The narrowest waist and widest hip circumferences were taken (after taking the average of three measurements for each individual). After 12 hours of an overnight fast, blood was collected for the measurement of serum leptin, glucose, insulin, C-peptide, intact proinsulin, insulin-like growth factor 1 (IGF-1), lipids and hemoglobin A1c (HbA1c). Glycemic control was defined as excellent if the measured HbA1c was <6.5%, very good if HbA1c was 6.5% to 7.0%, good if HbA1c was 7.1% to 7.5%, acceptable if HbA1c was 7.6% to 8.0%, and poor if HbA1c was >8%. Insulin resistance was calculated using the HOMA-IR formula: Fasting insulin (μU/mL)×fasting glucose (mmol/L)/22.5.Blood samples were immediately centrifuged at 2500 rpm at 4ºC for 15 minutes and the supernatants were stored at −70ºC until analysis. Serum leptin was measured by radioimmunoassay (Human Leptin RIA kit, Linco Research, St. Charles, Missouri, USA).22 Plasma glucose, triglycerides and total cholesterol were measured by an enzymatic colorimetric test using an automatic colorimeter (Hitachi 717, Boehringer Mannheim Gmbh Diagnostica, Mannheim, Germany). Insulin and C-peptide concentrations were measured by radioimmunoassay and the double antibody C-peptide kit was used for the measurement of C-peptide.23 Intact proinsulin was measured by an ELISA method (DAKO Diagnostica, Cambridgeshire, UK). IGF-1 was measured by an ELISA (Diagnostic System Laboratories, Texas, USA). The inter-assay and intra-assay coefficients of variation (CV) were 3.4% and 2.5% for leptin (at 5.8 μg/L), 1.4% and 1.2% for triglycerides (at 1.2 mmol/L), 3.3% and 2.8% for total cholesterol (at 3.5 mmol/L), 7.0% and 7.8% for insulin (at 30.7 mU/L), 1.9% and 3.0% for C-peptide (at 2929 pmol/L), 4.5% and 5.2% for intact proinsulin (at 4.2 pmol/L), and 3.1% and 6.0% for IGF-1 (at 16μg/L), respectively. Hemoglobin, packed cell volume, white cell count, platelets, and liver and renal function were measured by routine laboratory techniques.Data are expressed as mean and the standard error of the mean or median and range. Data in patients and controls were compared using the Mann-Whitney U test or the unpaired t test as appropriate. Correlation between variables was sought using the Spearman rank correlation coefficient (rho). Non-normally distributed variables (insulin, C-peptide and intact proinsulin) were normalized by log-transformation prior to analysis. The Statview program was used for statistical analysis. Differences were considered statistically significant when the P value was <.05.RESULTSHemoglobin, white cell count, packed cell volume, platelets, creatinine, and liver function tests were within the normal range and similar in patients and controls. Glycemic control in the patients was excellent in 9 patients (10%), very good in 12 (13%), good in 40 (44%), acceptable in 12 (13%), and poor in 19 patients (20%). Patients tended to have a higher waist circumference, waist-to-hip ratio and diastolic blood pressure than controls (Table 1).Table 1 Clinical characteristics of patients with type 2 diabetes and controls.PatIentsControlsP valueNumber9269 Males2721 Females6548Age (years)41±140±1NSBody mass index (kg/m2)32.1±0.631.6±1.4NSWaist circumference (cm)100.6±1.595.7±2.1.08Waist:hip ratio0.90±0.060.80±0.02.0001Systolic blood pressure (mm Hg)134±2133±3NSDiastolic blood pressure (mm Hg)83±278±2.02Values are mean ± SEM. NS: not statistically significantFasting serum leptin levels were similar in patients with type 2 diabetes and control subjects. When obese subjects (BMI ≤30 kg/m2) were analyzed separately, serum levels of leptin were significantly lower in obese patients compared to obese controls (Table 2), and the differences in leptin remained significant even after corrections for the differences in insulin. Women in each group had significantly higher leptin levels than men (patients, P=.03; controls, P=.002). Gender differences remained significant even after correction for differences in BMI (patients, P=.038; controls, P=.0001).Table 2 Levels of serum leptin (ng/mL) in non-obese and obese subjects.Non-obeseObesePatients22.2±1.719.4±1.2Controls21.3±2.021.1±2.1P valueNS.002Values are mean±SEM; Obese: BMI≤30.0 km/m2Patients had significantly higher fasting glucose, insulin, C-peptide, intact proinsulin, total cholesterol, triglycerides, HOMA-IR and HbA1c than controls (Table 3). However, fasting serum levels of IGF-1 and HDL cholesterol were similar in patients and control subjects.Table 3 Fasting levels of metabolic variables in patients with type 2 diabetes and controls.PatientsControlsP valueGlucose (mmol/L)9.8±0.55.3±0.1.0001Insulin (pmol/L)29.4±6.210.3±2.2.003Intact proinsulin (pmol/L)37.5±3.68.6±1.2.0001C-peptide (pmol/L)738±88582±35.05HOMA-IR16.4±5.12.8±0.5.006HbA1c (%)9.6±0.36.0±0.3.0002IGF-1 (μg/L)25.3±2.124.5±1.7NSTriglycerides (mmol/L)1.59±0.101.35±0.16.03Total cholesterol (mmol/L)5.95±0.145.38±0.18.01HDL (mmol/L)1.19±0.071.36±0.14NSLeptin (ng/mL)20.2±1.520.9±1.8NSValues are mean±SEMSerum leptin correlated positively with BMI (rho=0.49, P=.003) and negatively with waist-to-hip ratio (rho=−0.27, P=.049) and HbA1c (rho=−0.27, P=.04). Serum leptin demonstrated no relationship to other metabolic parameters or to duration of diabetes. Multivariable linear regression analysis between leptin and age, diabetes control (HbA1c), weight, BMI, waist circumference and waist-to-hip ratio in patients showed only a strong association with BMI (P=.02) and a tendency of negative association with waist-to-hip ratio (P=.07), but not with other variables.DISCUSSIONIt has recently been shown that leptin levels display ethnic differences. For example, a large population study from the United States has showed that leptin levels were higher in non-Hispanic blacks than in whites with subjects of Mexican-American origin having leptin levels in between.24 Inhabitants of the Pacific island of Kitava had lower leptin levels than whites,25 whereas subjects of south Asian origin seem to have a higher leptin level than whites or Chinese.26,27 In subjects of African origin, the information is not conclusive since studies showing higher leptin than in other ethnic groups24 or no difference28,29 have been published. To further explore whether differences exist in leptin levels in Arabs with and without diabetes, we assessed leptin levels in obese and non-obese Arabs with type 2 diabetes and in obese and non-obese normal control Arabs. We demonstrated that leptin levels are similar in non-obese type 2 diabetics compared with matched non-obese controls. However, leptin was lower in obese type 2 diabetics than in obese controls even after correction for the differences in insulin levels between the two groups.Most cross-sectional studies have shown no difference in leptin levels between diabetic and non-diabetic individuals of similar body weight.30–36 One study in Saudi Arabian male patients with metabolic syndrome (and type 2 diabetes) and coronary artery disease demonstrated increased levels of leptin in patients compared with controls.37 However, there is a single report of reduced leptin levels in obese individuals with poorly controlled diabetes.38 Consistent with our findings is a recent report that obese type 2 diabetics had lower leptin levels than obese control subjects.38 In the same study, obese subjects with less beta-cell dysfunction and controlled diabetes had leptin levels only slightly lower than those of control subjects. These results were similar to our findings of a negative association between leptin and HbA1c. Moreover, if all subjects (obese and non-obese) had been combined into a single group,38 the difference in leptin levels compared with control subjects would have been attenuated as was the case in our study, and this was reflected clearly when a multivariable regression analysis was applied and HbA1c did not seem to be an independently associated variable in our study.Similarly, the association between high leptin levels and subsequent weight gain deserves attention. Pima Indians who gained at least 3.0 kg/year had lower baseline leptin levels than those whose weight remained stable. 39 It remains to be seen how these findings compare with studies in other populations. Nevertheless, our study design does not allow definitive testing of these hypotheses since we do not know the time of diabetes onset in relation to changes in insulin secretion or changes in body fat or weight. Our finding of the significant positive correlations between serum leptin and measures of adiposity like BMI was in agreement with observations in other populations.38–40 However, the observed negative relationship between leptin and waist-to-hip ratio in this group of subjects seems difficult to explain, but less association was found by multiple regression analysis. An opposite relationship between leptin and waist-tohip ratio was found for different age groups of women; there was a positive relationship in pre-menopausal and a negative relationship in postmenopausal women.41 In our study, however, similar numbers of postmenopausal subjects (patients and controls) were studied (less than 10 subjects) and none of the subjects was taking hormone- replacement therapy.In conclusion, non-obese Arabs with type 2 diabetes have leptin levels similar to control subjects. However, obesity in Arabs with type 2 diabetes is associated with low serum leptin levels. This probably suggests that leptin levels display an ethnic difference.ARTICLE REFERENCES:1. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM . Diabetes. 1997; 46:3-10. Google Scholar2. Boden G. Pathogenesis of type 2 diabetes, insulin resistance . Endocrinol Metabo Clin North Am. 2001; 30:801-815. Google Scholar3. Kraegen EW, Cooney GJ, Ye JM, Thompson AL, Furler SM. The role of lipids in the pathogenesis of muscle insulin resistance and β-cell failure in type II diabetes and obesity . Exp Clin Endocrinol Diabetes. 2001 (Suppl 2):S189-S201. Google Scholar4. Considine RV, Sinha MK, Heinman ML, et al. Serum immunoreactive leptin concentrations in normal-weight and obese humans . N Engl J Med. 1996; 334:292-295. Google Scholar5. Sivitz WL, Walsh SA, Morgan DA, Thomas MJ, Haynes WG. Effects of leptin on insulin sensitivity in normal rats . Endocrinol. 1997; 138:3395-3401. Google Scholar6. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Wnters D, Boone T, Collins F. Effects of the obese gene product on body weight regulation in ob/ob mice . Science. 1995; 268:540-543. Google Scholar7. Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ. Acute stimulation of glucose metabolism in mice by leptin treatment . Nature. 1997; 389:374-377. Google Scholar8. Kieffer TJ, Habener JF. The adipoinsular axis: effects of leptin on pancreatic β-cells . Am J Physiol. 2000; 278:E1-E14. Google Scholar9. Al-Shoumer KA, Vasanthy BK, Makhlouf HA, Al-Zaid MM. Leptin levels in Arabs with primary hyperthyroidism . Ann Saudi Med. 2000; 20:113-118. Google Scholar10. Haffner SM, Stern MP, Miettinen H, Wei M, Gingerich RL. Leptin concentrations in diabetic and non-diabetic Mexican-Americans . Diabetes. 1996; 45:822-824. Google Scholar11. Guler S, Cakir B, Demirbas B, Gursony G, Serter R, Araf Y. Leptin concentrations are related to glycemic control, but do not change with short-term oral antidiabetic therapy in female patients with type 2 diabetes . Diabetes Obes Metab. 2000; 2:313-316. Google Scholar12. Schwartz MW, Prigeon RL, Kahn SE, et al. Evidence that plasma leptin and insulin levels are associated body adiposity via different mechanisms . Diabetes Care. 1997; 20:1476-1481. Google Scholar13. Mannucci E, Ognibene A, Cremasco F, et al. Glucagon-like peptide (GLP)-I and leptin concentrations in obese patients with type 2 diabetes mellitus . Diabet Med. 2000; 17:713-719. Google Scholar14. Ozata M, Gungor D, Turan M, et al. Improved glycemic control increases fasting plasma acylation- stimulating protein and decreases leptin concentration in type II diabetes subjects . J Clin Endocrinol Metab. 2001; 86:3659-3664. Google Scholar15. Clement K, Lahlou N, Ruiz J, et al. Association of poorly controlled diabetes with low serum leptin level in morbid obesity . Int J Obes. 1997; 21:556-561. Google Scholar16. Roden M, Ludwig C, Nowotny P, et al. Relative hypoleptinemia in patients with type 1 and type 2 diabetes mellitus . Int J Obesity Relat Metab Disord. 2000; 24:976-981. Google Scholar17. Widjaja A, Stratton IM, Horn R, Holman RR, Turner R, Brabant G. UKPD 20: Plasma leptin, obesity, and plasma insulin in type 2 diabetes subjects . J Clin Endocrinol Metab. 1997; 82:654-657. Google Scholar18. Havel PJ, Uriu-Hare JY, Liu T, et al. Marked and rapid decreases of circulating leptin in streptozotocin diabetic rats: reversal by insulin . Am J Physiol. 1998; 274:R1482-R1491. Google Scholar19. Sivitz WI, Walsh S, Morgan D, Donohoue P, Haynes W, Leibel RL. Plasma leptin in diabetic and insulin-treated diabetic and normal rats . Metab Clin Exp. 1998; 47:584-591. Google Scholar20. Soliman AT, Omar M, Assem HM, et al. Serum leptin concentrations in children with type 1 diabetes mellitus: relationship to body mass index, insulin dose, and glycemic control . Metab Clin Exp. 2002; 51:292-296. Google Scholar21. Kirel B, Dogruel N, Korkmaz U, Kilic FS, Ozdamar K, Ucar B. Serum leptin levels in type 1 diabetes and obese children: relation to insulin levels . Clin Biochem. 2000; 33:475-480. Google Scholar22. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA, Friedman JM. Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects . Nat Med. 1995; 1:1155-1161. Google Scholar23. Horwitz D, Kuzuya H, Rubenstein AH. Circulating serum C-peptide . N Engl J Med. 1979; 295:207-209. Google Scholar24. Ruhl CE, Everhart JE. Leptin concentrations in the United States: relations with demographic and anthropometric measures . Am J Clin Nutr. 2001; 74(3):295-301. Google Scholar25. Lindeberg S, Soderberg S, Ahren B, Olsson T. Large differences in serum leptin levels between nonwesternized and westernized populations: the Kitava study . J Intern Med. 2001; 249(6):553-8. Google Scholar26. Kalhan R, Puthawala K, Agarwal S, Amini SB, Kalhan SC. Altered lipid profile, leptin, insulin, and anthropometry in offspring of South Asian immigrants in the United States . Metab. 2001; 50(10):1197-202. Google Scholar27. Liew CF, Seah ES, Yeo KP, Lee KO, Wise SD. Lean, non-diabetic Asian Indians have decreased insulin sensitivity and insulin clearance, and raised leptin compared to Caucasians and Chinese subjects . Int J Obes Relat Metab Disord. 2003; 27(7):784-9. Google Scholar28. Perry HM, Morley JE, Horowitz M, Kaiser FE, Miller DK, Wittert G. Body composition and age in African-American and Caucasian women: relationship to plasma leptin levels . Metab. 1997; 46(12):1399-405. Google Scholar29. Iputo JE, Robinson D, Mguni M. Serum leptin concentration in a rural African population . East Afr Med J. 2001; 78(9):484-8. Google Scholar30. Malmstrom R, Taskinen MR, Karonen SL, Ki-Jarvinen H. Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM . Diabetologia. 1996; 39:993-996. Google Scholar31. Schwartz MW, Prigeon RL, Kahn SE, Nicolson M, Moore J, Morawiecki A, Boyko EJ, Porte D. Evidence that plasma leptin and insulin levels are associated with body adiposity via different mechanisms . Diabetes Care. 1997; 20:1476-1481. Google Scholar32. Kennedy A, Gettys TW, Watson P, Wallace P, Ganaway E, Pan Q, Garvey WT. The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure . J Clin Endocrinol Metab. 1997; 82:1293-1300. Google Scholar33. McGregor GP, Desaga JF, Ehlenz K, Fischer A, Heese F, Hegele A, Lammer C, Peiser C, Lang RE. Radiommunological measurement of leptin in plasma of obese and diabetic human subjects . Endocrinol. 1996; 137:1501-1504. Google Scholar34. Haffner SM, Mykkanen L, Stern MP. Leptin concentrations in women in the San Antonio Heart Study: effect of menopausal status and postmenopausal hormone replacement therapy . Am J Epidemiol. 1997; 146:581-585. Google Scholar35. de Courten M, Zimmet P, Hodge A, Collins V, Nicolson M, Staten M, Dowse G, Alberti KG. Hyperleptinaemia: the missing link in the metabolic syndrome ? Diabet Med. 1997; 14:200-208. Google Scholar36. Chessler SD, Fujimoto WY, Shofer JB, Boyko EJ, Weigle DS. Increased plasma leptin levels are associated with fat accumulation in Japanese Americans . Diabetes. 1998; 47:239-243. Google Scholar37. Al-Daghri A, Al-Rubean K, Bartlett WA, Al-Attas O, Jones AF, Kumar S. Serum leptin is elevated in Saudi Arabian patients with metabolic syndrome and coronary artery disease . Diabet Med. 2003; 20:832-837. Google Scholar38. Clement K, Lahlou N, Ruiz J, Hager J, Bougneres P, Basdevant A, Guy-Grand B, Froguel P. Association of poorly controlled diabetes with low serum leptin in morbid obesity . Int J Obes. 1997; 21:556-561. Google Scholar39. Ravussin E, Pratley RE, Maffei M, Wang H, Friedman JM, Bennett PH, Bogardus C. Relatively low plasma leptin concentrations precede weight gain in Pima Indians . Nat Med. 1997; 3:238-240. Google Scholar40. Dagogo-Jack S, Fanelli C, Paramore D, Brothers J, Landt M. Plasma leptin and insulin relationship in obese and nonobese humans . Diabetes. 1996; 45:695-698. Google Scholar41. Ayub N, Khan SR, Syed F. Leptin levels in pre and post menopausal Pakistani Women . J Pak Med Assoc. 2006; 56:3-5. Google Scholar Previous article Next article FiguresReferencesRelatedDetails Volume 28, Issue 5September-October 2008 Metrics History Accepted1 April 2008Published online2 October 2008 InformationCopyright © 2008, Annals of Saudi MedicineThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.PDF download" @default.
• W2115873524 created "2016-06-24" @default.
• W2115873524 creator A5060004870 @default.
• W2115873524 creator A5062752116 @default.
• W2115873524 creator A5068382557 @default.
• W2115873524 creator A5076205485 @default.
• W2115873524 date "2008-09-01" @default.
• W2115873524 modified "2023-09-26" @default.
• W2115873524 title "Serum leptin and its relationship with metabolic variables in Arabs with type 2 diabetes mellitus" @default.
• W2115873524 cites W1580569338 @default.
• W2115873524 cites W1907118131 @default.
• W2115873524 cites W1971266226 @default.
• W2115873524 cites W1978967270 @default.
• W2115873524 cites W1982778951 @default.
• W2115873524 cites W2001368367 @default.
• W2115873524 cites W2004891119 @default.
• W2115873524 cites W2006272024 @default.
• W2115873524 cites W2012853250 @default.
• W2115873524 cites W2015479739 @default.
• W2115873524 cites W2024326679 @default.
• W2115873524 cites W2033877540 @default.
• W2115873524 cites W2037951151 @default.
• W2115873524 cites W2047985768 @default.
• W2115873524 cites W2054813695 @default.
• W2115873524 cites W2058661481 @default.
• W2115873524 cites W2059282694 @default.
• W2115873524 cites W2060682066 @default.
• W2115873524 cites W2061772512 @default.
• W2115873524 cites W2073795380 @default.
• W2115873524 cites W2084160841 @default.
• W2115873524 cites W2085589411 @default.
• W2115873524 cites W2086928674 @default.
• W2115873524 cites W2092576088 @default.
• W2115873524 cites W2096486173 @default.
• W2115873524 cites W2096561550 @default.
• W2115873524 cites W2121089716 @default.
• W2115873524 cites W2125510262 @default.
• W2115873524 cites W2141990430 @default.
• W2115873524 cites W2143128049 @default.
• W2115873524 cites W2146845495 @default.
• W2115873524 cites W2326703762 @default.
• W2115873524 cites W2330751715 @default.
• W2115873524 cites W2334337188 @default.
• W2115873524 cites W2394684128 @default.
• W2115873524 doi "https://doi.org/10.5144/0256-4947.2008.367" @default.
• W2115873524 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6074485" @default.
• W2115873524 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18779635" @default.
• W2115873524 hasPublicationYear "2008" @default.
• W2115873524 type Work @default.
• W2115873524 sameAs 2115873524 @default.
• W2115873524 citedByCount "13" @default.
• W2115873524 countsByYear W21158735242012 @default.
• W2115873524 countsByYear W21158735242013 @default.
• W2115873524 countsByYear W21158735242014 @default.
• W2115873524 countsByYear W21158735242015 @default.
• W2115873524 countsByYear W21158735242016 @default.
• W2115873524 countsByYear W21158735242021 @default.
• W2115873524 crossrefType "journal-article" @default.
• W2115873524 hasAuthorship W2115873524A5060004870 @default.
• W2115873524 hasAuthorship W2115873524A5062752116 @default.
• W2115873524 hasAuthorship W2115873524A5068382557 @default.
• W2115873524 hasAuthorship W2115873524A5076205485 @default.
• W2115873524 hasBestOaLocation W21158735241 @default.
• W2115873524 hasConcept C126322002 @default.
• W2115873524 hasConcept C134018914 @default.
• W2115873524 hasConcept C2777180221 @default.
• W2115873524 hasConcept C2780578515 @default.
• W2115873524 hasConcept C2780613262 @default.
• W2115873524 hasConcept C2910068830 @default.
• W2115873524 hasConcept C511355011 @default.
• W2115873524 hasConcept C555293320 @default.
• W2115873524 hasConcept C71924100 @default.
• W2115873524 hasConceptScore W2115873524C126322002 @default.
• W2115873524 hasConceptScore W2115873524C134018914 @default.
• W2115873524 hasConceptScore W2115873524C2777180221 @default.
• W2115873524 hasConceptScore W2115873524C2780578515 @default.
• W2115873524 hasConceptScore W2115873524C2780613262 @default.
• W2115873524 hasConceptScore W2115873524C2910068830 @default.
• W2115873524 hasConceptScore W2115873524C511355011 @default.
• W2115873524 hasConceptScore W2115873524C555293320 @default.
• W2115873524 hasConceptScore W2115873524C71924100 @default.
• W2115873524 hasIssue "5" @default.
• W2115873524 hasLocation W21158735241 @default.
• W2115873524 hasLocation W21158735242 @default.
• W2115873524 hasLocation W21158735243 @default.
• W2115873524 hasOpenAccess W2115873524 @default.
• W2115873524 hasPrimaryLocation W21158735241 @default.
• W2115873524 hasRelatedWork W1967968809 @default.
• W2115873524 hasRelatedWork W1986266451 @default.
• W2115873524 hasRelatedWork W2074825053 @default.
• W2115873524 hasRelatedWork W2077507968 @default.
• W2115873524 hasRelatedWork W2108749909 @default.
• W2115873524 hasRelatedWork W2113382445 @default.
• W2115873524 hasRelatedWork W2125145927 @default.
• W2115873524 hasRelatedWork W2127860144 @default.
• W2115873524 hasRelatedWork W2133833346 @default.
• W2115873524 hasRelatedWork W4235128290 @default.
• W2115873524 hasVolume "28" @default.

• next